A Phase 2 interventional study of Panitumumab in Colorectal Cancer and Metastatic Cancer, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-01-10.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies testing panitumumab in Colorectal Neoplasms — 7 open to participants now, 12 under way, 3 of them phase 3. Panitumumab · Colorectal Neoplasms.
Among the 90 studies testing panitumumab in Colorectal Neoplasms, this one is the 22nd largest by enrollment of the 88 interventional ones that give a count, is one of 4 that started in 2004, is one of 60 in phase 2, and was the 3rd registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →7 of the 90 studies testing panitumumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
AbbVie · Sites in United States, Australia, Austria and 12 more countries
Ages 18+
R-Pharm · Sites in Russia
Ages 18+
UNICANCER · Sites in France
Ages 18+
Amgen · Sites in United States, Argentina, Australia and 32 more countries
Ages 18+
By country, each count listing its studies:
Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 68 · Phase 3 15 · Phase 4 1
First in 2000; this study’s year is marked. 4 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 185 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 70 across the 88 interventional studies. Of the 67 that completed or were terminated, 30 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 90 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
40 studies in Colorectal Neoplasms by Amgen: 2 open now, 2 under way, 1 of them phase 3. Of 38 finished, 24 (63%) have results posted.
Among the 40 studies in Colorectal Neoplasms by Amgen, this one is the 15th largest by enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2004, is one of 16 in phase 2, and was the 1st registered.
Amgen’s Colorectal Neoplasms studies by the year they started, since 2002.
3 of the studies testing panitumumab in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03087071M.D. Anderson Cancer CenterPanitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer | 2027-01-31 |
| NCT05845450Gruppo Oncologico del Nord-OvestPre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) | 2027-05 |
| NCT07318389M.D. Anderson Cancer CenterASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer | 2027-11-14 |
Add all 3 to your calendar (.ics) → With an account.
Among the 90 studies testing panitumumab in Colorectal Neoplasms, from their registry updates:
Among Amgen’s 40 in Colorectal Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine that panitumumab will have clinically meaningful anti-tumor activity in patients with metastatic colorectal cancer who have developed progressive disease or relapsed while on or after prior fluoropyrimidine, irinotecan and oxaliplatin chemotherapy.
Panitumumab was administered once every 2 weeks until participants developed progressive disease, were unable to tolerate panitumumab, or discontinued treatment for other reasons (eg, administrative decision). Participants then attended a safety follow-up visit 4 weeks from the last panitumumab infusion. Participants were subsequently contacted every 3 months from the last panitumumab infusion through month 24 to assess disease status and survival.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received panitumumab 6 mg/kg once every 2 weeks weeks administered by intravenous (IV) infusion until progressive disease, inability to tolerate the investigational product, or discontinuation of treatment for other reasons.
Biological: Panitumumab
Panitumumab 6 mg/kg every once 2 weeks weeks administered by intravenous (IV) infusion.
Also known as: ABX-EGF, Vectibix
Number of Participants With Objective Tumor Response Through Week 16
Confirmed objective tumor response (complete or partial response) based on modified World Health Organization (WHO) criteria, through week 16. Tumor response was assessed by a central Independent Review Committee (IRC) and confirmation 4 weeks after initial assessment was required. Complete Response (CR): Disappearance of all index and non-index lesions and no new lesions. Partial Response (PR): At least a 50% decrease in the sum of the product of the longest diameters (SPD) of index lesions taking as reference the Baseline SPD, and no new non-index lesions and no "unequivocal progression" of non-index lesions, or, the disappearance of all index lesions and persistence of one or more non-index lesions not qualifying for either CR or Progressive Disease.
Time frame: 16 weeks
Duration of Response
The time from first objective response to first observed progression of disease or death if the death was due to disease progression (whichever comes first); participants who respond and have not progressed while on study or died for reasons other than disease progression while on study were censored at their last evaluable disease assessment date. Response (complete or partial response) was assessed per modified WHO criteria by the central IRC. Complete Response (CR): Disappearance of all index and non-index lesions and no new lesions. Partial Response (PR): At least a 50% decrease in the sum of the product of the longest diameters (SPD) of index lesions taking as reference the Baseline SPD, and no new non-index lesions and no "unequivocal progression" of non-index lesions, or, the disappearance of all index lesions and persistence of one or more non-index lesions not qualifying for either CR or Progressive Disease.
Time frame: Until the data cut-off date of 22 December 2006. Maximum time of follow-up was 128 weeks.
Number of Participants With Objective Tumor Response Throughout Study
Confirmed objective tumor response (complete or partial response) based on modified World Health Organization (WHO) criteria, throughout the duration of the study Tumor response was assessed by a central Independent Review Committee (IRC) and confirmation 4 weeks after initial assessment was required. Complete Response (CR): Disappearance of all index and non-index lesions and no new lesions. Partial Response (PR): At least a 50% decrease in the sum of the product of the longest diameters (SPD) of index lesions taking as reference the Baseline SPD, and no new non-index lesions and no "unequivocal progression" of non-index lesions, or, the disappearance of all index lesions and persistence of one or more non-index lesions not qualifying for either CR or Progressive Disease.
Time frame: Until the data cut-off date of 22 December 2006. Maximum time of follow-up was 128 weeks.
Time to Response
Median time from enrollment to objective tumor response for participants who responded.
Time frame: Until the data cut-off date of 22 December 2006. Maximum time of follow-up was 128 weeks.
Progression-free Survival Time
Kaplan-Meier estimate of median time from enrollment to death or first observed disease progression (whichever comes first). Participants who did not progress while on study and did not die while on study were censored at the last evaluable disease assessment date.
Time frame: Until the data cut-off date of 22 December 2006. Maximum follow-up time was 128 weeks.
Time to Disease Progression
Kaplan-Meier estimate of the median time from enrollment to first observed disease progression or death if death was due to disease progression (whichever comes first). Participants who did not progress while on study or died for reasons other than disease progression while on study were censored at their last evaluable disease assessment date.
Time frame: Until the data cut-off date of 22 December 2006. Maximum follow-up time was 128 weeks.
Time to Treatment Failure
Kaplan-Meier estimate of median time from enrollment to treatment failure, defined as the date the decision was made to end treatment. Participants remaining in the treatment phase at the time of the analysis were censored on their last visit date.
Time frame: Until the data cut-off date of 22 December 2006. Maximum follow-up time was 128 weeks.
Duration of Stable Disease
Kaplan-Meier estimates of the median time from enrollment to the date of first observed disease progression or death due to disease progression among those participants with a best outcome of stable disease. Stable disease (SD): Neither sufficient shrinkage of Index lesions to qualify for partial response nor sufficient increase to qualify for progressive disease (PD) taking as reference the nadir sum of the products of the longest diameters (SPD) since the treatment started and the disappearance of or persistence of one or more non-index lesions not qualifying for PD.
Time frame: Until the data cut-off date of 22 December 2006. Maximum follow-up time was 128 weeks.
Overall Survival
Kaplan-Meier estimate of median time from enrollment to death from any cause. Deaths were recorded during treatment, safety follow-up and long term follow-up.
Time frame: Until the data cut-off date of 22 December 2006. Maximum follow-up time was 128 weeks.
Participants were enrolled from 1 March 2004 through 19 Jul 2006. Patient disposition is reported up until the data cut-off date of 22 December 2006. Completed study is defined as participants who either died on study or completed the safety follow-up visit (30 days after the last dose of panitumumab).
| Milestone | Panitumumab (ABX-EGF) |
|---|---|
| Started | 185 |
| Received study medication | 182 |
| Completed | 154 |
| Not completed | 31 |
| Withdrew: Disease progression | 16 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Physician decision | 2 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Ineligibility determined | 2 |
| Withdrew: Non-compliance | 1 |
| Withdrew: Other | 6 |
Confirmed objective tumor response (complete or partial response) based on modified World Health Organization (WHO) criteria, through week 16. Tumor response was assessed by a central Independent Review Committee (IRC) and confirmation 4 weeks after initial assessment was required. Complete Response (CR): Disappearance of all index and non-index lesions and no new lesions. Partial Response (PR): At least a 50% decrease in the sum of the product of the longest diameters (SPD) of index lesions taking as reference the Baseline SPD, and no new non-index lesions and no "unequivocal progression" of non-index lesions, or, the disappearance of all index lesions and persistence of one or more non-index lesions not qualifying for either CR or Progressive Disease.
| Participants | Panitumumab |
|---|---|
| Number of Participants With Objective Tumor Response Through Week 16 | 5 |
The time from first objective response to first observed progression of disease or death if the death was due to disease progression (whichever comes first); participants who respond and have not progressed while on study or died for reasons other than disease progression while on study were censored at their last evaluable disease assessment date. Response (complete or partial response) was assessed per modified WHO criteria by the central IRC. Complete Response (CR): Disappearance of all index and non-index lesions and no new lesions. Partial Response (PR): At least a 50% decrease in the sum of the product of the longest diameters (SPD) of index lesions taking as reference the Baseline SPD, and no new non-index lesions and no "unequivocal progression" of non-index lesions, or, the disappearance of all index lesions and persistence of one or more non-index lesions not qualifying for either CR or Progressive Disease.
| Weeks | Panitumumab |
|---|---|
| Duration of Response | 14.0 (12.4 to 101.7) |
Confirmed objective tumor response (complete or partial response) based on modified World Health Organization (WHO) criteria, throughout the duration of the study Tumor response was assessed by a central Independent Review Committee (IRC) and confirmation 4 weeks after initial assessment was required. Complete Response (CR): Disappearance of all index and non-index lesions and no new lesions. Partial Response (PR): At least a 50% decrease in the sum of the product of the longest diameters (SPD) of index lesions taking as reference the Baseline SPD, and no new non-index lesions and no "unequivocal progression" of non-index lesions, or, the disappearance of all index lesions and persistence of one or more non-index lesions not qualifying for either CR or Progressive Disease.
| Participants | Panitumumab |
|---|---|
| Number of Participants With Objective Tumor Response Throughout Study | 5 |
Median time from enrollment to objective tumor response for participants who responded.
| Weeks | Panitumumab |
|---|---|
| Time to Response | 11.0 (7.7 to 11.1) |
Kaplan-Meier estimate of median time from enrollment to death or first observed disease progression (whichever comes first). Participants who did not progress while on study and did not die while on study were censored at the last evaluable disease assessment date.
| Weeks | Panitumumab |
|---|---|
| Progression-free Survival Time | 7.3 (7.1 to 7.4) |
Kaplan-Meier estimate of the median time from enrollment to first observed disease progression or death if death was due to disease progression (whichever comes first). Participants who did not progress while on study or died for reasons other than disease progression while on study were censored at their last evaluable disease assessment date.
| Weeks | Panitumumab |
|---|---|
| Time to Disease Progression | 7.3 (7.1 to 7.6) |
Kaplan-Meier estimate of median time from enrollment to treatment failure, defined as the date the decision was made to end treatment. Participants remaining in the treatment phase at the time of the analysis were censored on their last visit date.
| Weeks | Panitumumab |
|---|---|
| Time to Treatment Failure | 8.0 (7.4 to 8.1) |
Kaplan-Meier estimates of the median time from enrollment to the date of first observed disease progression or death due to disease progression among those participants with a best outcome of stable disease. Stable disease (SD): Neither sufficient shrinkage of Index lesions to qualify for partial response nor sufficient increase to qualify for progressive disease (PD) taking as reference the nadir sum of the products of the longest diameters (SPD) since the treatment started and the disappearance of or persistence of one or more non-index lesions not qualifying for PD.
| Weeks | Panitumumab |
|---|---|
| Duration of Stable Disease | 23.9 (23.0 to 31.0) |
Kaplan-Meier estimate of median time from enrollment to death from any cause. Deaths were recorded during treatment, safety follow-up and long term follow-up.
| months | Panitumumab |
|---|---|
| Overall Survival | 7.0 (5.7 to 8.0) |
Collected over From the first dose through maximum of safety follow-up or 30 days after last dose; maximum time on study treatment was 1.25 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Panitumumab | — | 62/182 (34.1%) | 176/182 (96.7%) |
| Event | Panitumumab |
|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 7/182 |
| Small intestinal obstructionGastrointestinal disorders | 6/182 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/182 |
| Colon cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/182 |
| Colorectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 5/182 |
| Abdominal painGastrointestinal disorders | 4/182 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 4/182 |
| Abdominal distensionGastrointestinal disorders | 3/182 |
| AscitesGastrointestinal disorders | 3/182 |
| PneumoniaInfections and infestations | 3/182 |
| Event | Panitumumab |
|---|---|
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 125/182 |
| ErythemaSkin and subcutaneous tissue disorders | 112/182 |
| PruritusSkin and subcutaneous tissue disorders | 96/182 |
| FatigueGeneral disorders | 66/182 |
| NauseaGastrointestinal disorders | 58/182 |
| DiarrhoeaGastrointestinal disorders | 48/182 |
| RashSkin and subcutaneous tissue disorders | 44/182 |
| VomitingGastrointestinal disorders | 38/182 |
| ConstipationGastrointestinal disorders | 36/182 |
| Abdominal painGastrointestinal disorders | 34/182 |
| Age, Continuous(Years) | Panitumumab |
|---|---|
| Mean | 59.6 ± 10.6 |
| Sex: Female, Male(Participants) | Panitumumab |
|---|---|
| Female | 85 |
| Male | 100 |
| Race/Ethnicity, Customized(Participants) | Panitumumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 4 |
| Black or African American | 15 |
| Hispanic or Latino | 19 |
| Japanese | 0 |
| Native Hawaiian or Other Pacific Islander | 1 |
| White or Caucasian | 144 |
| Other | 2 |
| Aborigine | 0 |
No study locations are listed for this record.
The record gives a start of Mar 2004, a primary completion of May 2007 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2011, 4 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Panitumumab